CN111269945A - Method for constructing retinal pigment degeneration disease model by using Gm20541 gene and application - Google Patents
Method for constructing retinal pigment degeneration disease model by using Gm20541 gene and application Download PDFInfo
- Publication number
- CN111269945A CN111269945A CN202010114903.8A CN202010114903A CN111269945A CN 111269945 A CN111269945 A CN 111269945A CN 202010114903 A CN202010114903 A CN 202010114903A CN 111269945 A CN111269945 A CN 111269945A
- Authority
- CN
- China
- Prior art keywords
- gene
- retinal pigment
- pigment degeneration
- disease model
- degeneration disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 71
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 70
- 201000007737 Retinal degeneration Diseases 0.000 title claims abstract description 55
- 238000000034 method Methods 0.000 title claims abstract description 37
- 241001465754 Metazoa Species 0.000 claims abstract description 22
- 230000002207 retinal effect Effects 0.000 claims abstract description 20
- 239000002243 precursor Substances 0.000 claims abstract description 19
- 210000001525 retina Anatomy 0.000 claims description 29
- 241000699670 Mus sp. Species 0.000 claims description 25
- 210000004027 cell Anatomy 0.000 claims description 25
- 238000003209 gene knockout Methods 0.000 claims description 23
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims description 20
- 229940000406 drug candidate Drugs 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 9
- 238000005516 engineering process Methods 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 8
- 241000124008 Mammalia Species 0.000 claims description 7
- 238000012216 screening Methods 0.000 claims description 6
- 238000009395 breeding Methods 0.000 claims description 4
- 230000001488 breeding effect Effects 0.000 claims description 4
- 230000004438 eyesight Effects 0.000 claims description 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 4
- 210000000768 retinal photoreceptor cell outer segment Anatomy 0.000 claims description 3
- 241000282693 Cercopithecidae Species 0.000 claims description 2
- 241000283690 Bos taurus Species 0.000 claims 1
- 241000282472 Canis lupus familiaris Species 0.000 claims 1
- 241000283086 Equidae Species 0.000 claims 1
- 241001272567 Hominoidea Species 0.000 claims 1
- 241000283973 Oryctolagus cuniculus Species 0.000 claims 1
- 241001494479 Pecora Species 0.000 claims 1
- 241000700159 Rattus Species 0.000 claims 1
- 241000282887 Suidae Species 0.000 claims 1
- 238000011160 research Methods 0.000 abstract description 10
- 230000007246 mechanism Effects 0.000 abstract description 5
- 238000010171 animal model Methods 0.000 abstract description 3
- 230000002265 prevention Effects 0.000 abstract description 2
- 230000008569 process Effects 0.000 abstract description 2
- 230000001717 pathogenic effect Effects 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 47
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 20
- 210000001519 tissue Anatomy 0.000 description 16
- 230000003321 amplification Effects 0.000 description 10
- 238000011813 knockout mouse model Methods 0.000 description 10
- 238000003199 nucleic acid amplification method Methods 0.000 description 10
- 239000000243 solution Substances 0.000 description 9
- 239000002299 complementary DNA Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 101000976577 Homo sapiens Zinc finger protein 124 Proteins 0.000 description 7
- 102100023573 Zinc finger protein 124 Human genes 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 210000001508 eye Anatomy 0.000 description 7
- 238000003757 reverse transcription PCR Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 238000010276 construction Methods 0.000 description 6
- 230000004300 dark adaptation Effects 0.000 description 6
- 210000002216 heart Anatomy 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 210000005252 bulbus oculi Anatomy 0.000 description 5
- 230000030833 cell death Effects 0.000 description 5
- 210000004087 cornea Anatomy 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 239000008096 xylene Substances 0.000 description 5
- 108091033409 CRISPR Proteins 0.000 description 4
- 108091023040 Transcription factor Proteins 0.000 description 4
- 102000040945 Transcription factor Human genes 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical group [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 4
- 230000013011 mating Effects 0.000 description 4
- 239000012188 paraffin wax Substances 0.000 description 4
- 230000008506 pathogenesis Effects 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 description 3
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 102000004330 Rhodopsin Human genes 0.000 description 3
- 108090000820 Rhodopsin Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000006978 adaptation Effects 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 230000003950 pathogenic mechanism Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000011830 transgenic mouse model Methods 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 2
- 238000010354 CRISPR gene editing Methods 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 201000003863 Dandy-Walker Syndrome Diseases 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 238000010459 TALEN Methods 0.000 description 2
- 239000006180 TBST buffer Substances 0.000 description 2
- 101710185494 Zinc finger protein Proteins 0.000 description 2
- 102100023597 Zinc finger protein 816 Human genes 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 238000010805 cDNA synthesis kit Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 101150036876 cre gene Proteins 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000004301 light adaptation Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 108091008695 photoreceptors Proteins 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 101100005916 Arabidopsis thaliana CER3 gene Proteins 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 101100295848 Drosophila melanogaster Optix gene Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 101150088221 FLP1 gene Proteins 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 101100299619 Mus musculus Ptpn18 gene Proteins 0.000 description 1
- 208000006550 Mydriasis Diseases 0.000 description 1
- 208000001140 Night Blindness Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 208000032400 Retinal pigmentation Diseases 0.000 description 1
- 235000011449 Rosa Nutrition 0.000 description 1
- 101100220842 Schizosaccharomyces pombe (strain 972 / ATCC 24843) clp1 gene Proteins 0.000 description 1
- 108700010572 Sine oculis homeobox homolog 3 Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 239000008049 TAE buffer Substances 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- HGEVZDLYZYVYHD-UHFFFAOYSA-N acetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound CC(O)=O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O HGEVZDLYZYVYHD-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 210000003986 cell retinal photoreceptor Anatomy 0.000 description 1
- 230000021617 central nervous system development Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 238000002001 electrophysiology Methods 0.000 description 1
- 230000007831 electrophysiology Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- DZGCGKFAPXFTNM-UHFFFAOYSA-N ethanol;hydron;chloride Chemical compound Cl.CCO DZGCGKFAPXFTNM-UHFFFAOYSA-N 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000002637 mydriatic agent Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 210000004492 nuclear pore Anatomy 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000000608 photoreceptor cell Anatomy 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 210000004129 prosencephalon Anatomy 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 210000003660 reticulum Anatomy 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Environmental Sciences (AREA)
- Organic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Biophysics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses a method for constructing a retinal pigment degeneration disease model by using a Gm20541 gene and application, and relates to the technical field of medical engineering. According to the method, the Gm20541 gene sequence in the genome of the retinal precursor cell is specifically targeted and knocked out, so that a target animal shows typical retinal pigment degeneration disease characteristics, a reliable animal model is provided for the research of the retinal pigment degeneration disease related to the Gm20541 gene, the pathogenic process and mechanism of the retinal pigment degeneration disease can be clarified, a new target is provided for the treatment or prevention of the retinal pigment degeneration disease, and the application prospect is wide.
Description
Technical Field
The invention relates to the technical field of medical engineering, in particular to a method for constructing a retinal pigment degeneration disease model by using a Gm20541 gene and application thereof.
Background
Retinitis Pigmentosa (RP) is a group of hereditary blinding fundus diseases caused by abnormal retinal photoreceptors, the worldwide incidence rate is about 1/3000-1/4000, the incidence rate of Chinese people can reach 1/3500, and due to the large population of China, RP patients can reach three hundred thousand, and heavy burden is brought to families and society. At present, diagnosis and treatment of RP face many difficulties, and no effective treatment means exists, which is mainly due to high heterogeneity of clinical phenotype and heredity and insufficient systematic research of pathological mechanism. The typical RP patients first develop night blindness and visual field stenosis due to rod cell function defects, gradually developing into tubular visual fields until blindness; retinal pigmentation was visible by fundus examination. Pathologically, the classical RP affects predominantly rod cells, causing rod cell death and secondary cone cell death, mainly manifested by photoreceptor damage, degeneration, progressive thinning of the outer retinal nuclear layer until it disappears, and corresponding pathological changes in the outer retinal layer and other related cell layers.
In addition, due to the high heterogeneity of RP in clinical phenotype and genetic pattern, many pathogenic mechanisms of RP are not yet clear, which brings great difficulty to clinical diagnosis and treatment of RP diseases, and thus research on pathogenic mechanisms of RP diseases is urgent.
At present, however, there is a lack of corresponding RP disease models.
Disclosure of Invention
The invention aims to provide a method for constructing a retinal pigment degeneration disease model by utilizing a Gm20541 gene and application thereof, the retinal pigment degeneration disease model can be obtained by adopting the construction method, the model can show the characteristics of the retinal pigment degeneration disease, the model can be used for researching the retinal pigment degeneration disease, can help to clarify the pathogenesis and mechanism of RP, and provides a new target for the treatment or prevention of the disease.
The invention is realized by the following steps:
in a first aspect, embodiments of the present invention provide a method for constructing a retinal pigment degeneration disease model using a Gm20541 gene, including: knocking out Gm20541 gene in the genome of the retina precursor cell of the target animal.
Znf124 is a novel gene encoding a zinc finger protein. Zinc finger proteins are transcription factors with finger-like domains, and play an important role in gene regulation. ZNF124 protein can enter nucleus through nuclear pore and can be used as transcription factor to regulate the expression of other genes. The current research on the function of the ZNF124 protein is not reported and the function is not known much, and the ZNF124 is related to Dandy-Walker complex (DWC) which is a congenital central nervous system development disease. Furthermore, ZNF124 is thought to be involved in the inhibition of human hematopoietic apoptosis by precursor growth factor (VEGF), suggesting that ZNF124 plays an important role in human life activities.
Another study of the inventors shows that Znf124 gene mutation is related to RP, which is greatly helpful for exploring pathogenic mechanism of RP. Therefore, the ZNF124 has great potential in the treatment and the cause discussion of the retinal pigment degeneration diseases. However, the present research on ZNF124 is still in the early stage, and the mouse homologous gene is Gm20541(predicted gene 20541, MGI: 5142006), the gene is located on mouse chromosome 17 No. 38009647 and 38012396bp, the full length is 2750kb, the cDNA full length is 1406 bp, comprises 3 exons, and the cDNA sequence is shown in SEQ ID NO.1 as follows: GAATGCAGTGACCTATGATGATGTGTGTGTGAACTTCACTCTGGAAGA ATGGACTTTACTGGATCCTTCACAGAAGAGTCTCTACAGAGATGTGAT GCAGGAAACCTACAGGAATCTCACTGCTATAGGCTACAATTGGGAAGA TGACAATATTGAAGACTATTTTCAAAGTTCTAGAAGACATGGAAGGCA TGAAAGAAATCATAGTGGAGAGAAACCTTATGCTTGTAACCAATGTGA TAAAGCCTTTTCATGTCATCATAGTCTCCAAATACATAAAAGAAGACAT ACTGGAGAGAAACTCTATGAATGTAACCGTTGTAATAAAGGCTTTCCA TATCCCAGTGCTCTACAAATACATAAAAGGATACACAGTGGAGAGAAA CCCTATGAATGTAAACAATGTGGTAAAGCCTTTGCATGTCACAGTTCT CTTCAAAGGCATGAAAGAATACATACTGGTGAGAAACCTTATGAATGTAGCCAATGTGGTAAAGCCTTTACACATCAAAAGAGTCTCCAAATACAT AAAAGAACTCACAGTGGAGAAAAACCATATGGGTGTAGTCAGTGTGG AAAAGACTTTGTAAGTCAGAGTCGTCTTCTAGAACATAAAAGGACAC ATACTGGAGAGAAACCCTATGAATGTAACCAATGTGGTAAAGCCTTTG CATATTCCAACAGTCTCCAAATACATCAAAGAACACACACTGGAGAG AAACCCTATGAATGTAACCAGTGTGGTAAAGCCTTTGCATATCACAAT AGTCTCCAAATACATAAAAGTACACACACTGGAGAGAAACCCTATAAA TGTAACCAGTGTGGTAAAGCCTTTGCATATCACATTACTCTCCGAACA CATAAAGGAACACACACTGAAGAGAAACCCTATGAATGTAACCAATG TGGTAAAGCCTTTGCATATTCCAACAGTCTCCAAATACATCAAAGAAC ACACACTGGAGAGAAACCCTATGAATGTAACCAGTGTGGTAAAGCCT TTGCATATCACAATAGTCTCCAAATACATAAAAGTACACACACTGGAG AGAAACCCTATGAATGTAACCAGTGTGGTAAAGCCTTTGTATGTAGCA GTCATTTTCAAAGGCATAAAAAAATTCATACTGGAGAGAAACCCTATG ATTGTAACCAGTGTGGTAAAGCCTTTGCATATAAAAGTAATCTCCAAAT TCATGAAAGAAAACACACTGGAGGGAAACCCTCTGAATGTAATTAAT GTAGTAAAGCTTTTGCATTTCATAATAGTTTCCAAATACATAAAAGAAC ACATAGTGAGAGAAACCCTATGAATATAACCAATGTGGTAAAACATTT CCATATCTCAGTGGTCTCCGCATTTATAACAGAACACATAGTGGAGAG AAACCCTATGGATGTAA are provided.
The specific action mechanism of Gm20541 in mice is not clear, and the development and application of the Gm20541 are limited. To date, there is no functional study on the Gm20541 gene, and the biological function thereof is unclear.
The inventor of the invention firstly discovers that the target animal can show the characteristics related to the retinitis pigmentosa diseases such as rod cell death and secondary cone cell death, mainly as damaged and degenerated photoreceptors, the outer nuclear layer of the retina is gradually thinned until disappears, and the outer retinal reticulum layer and other related cell layers show corresponding pathological changes by knocking out the Gm20541 gene, namely silencing or knocking down the expression of the Gm20541 gene in the precursor cells of the retina of the target animal such as a mouse. Therefore, the animal with the Gm20541 gene knocked out in the retinal precursor cell can be used as a retinal pigment degeneration disease model, is used in the fields of research on retinal pigment degeneration diseases and the like, and provides a new model for the research on the diseases, such as the pathogenesis, and the screening of related medicines.
Further, in some embodiments of the invention, knockout of the Gm20541 gene sequence refers to knockout of an exon sequence of the Gm20541 gene.
The sequence of the Gm20541 gene knockout can be a sequence of the Gm20541 gene in the full length, or can be a sequence of a part of the Gm20541 gene, such as a part of exon sequence, and the sequence of any type (part or full length) can be knocked out, so long as the sequence can silence the expression of the Gm20541 gene in precursor cells, and the corresponding characteristics of the retinitis pigmentosa diseases can be expressed by animals, which falls into the protection scope of the invention.
Further, in some embodiments of the invention, the exon sequences are selected from any one or more of exon 1, exon 2, and exon 3 sequences.
On the basis of the disclosure of the present invention, that is, on the premise that the present invention reveals the correlation between the Gm20541 gene and the retinal pigment degeneration disease, one skilled in the art can easily think of knocking out any one or more exon sequences of the Gm20541 gene, so as to damage the function of the Gm20541 gene and further obtain a similar retinal pigment degeneration disease model, and such methods also belong to the protection scope of the present invention.
Further, in some embodiments of the invention, the exon sequences are exon 3 sequences.
Further, in some embodiments of the invention, the 3 rd exon sequence on the Gm20541 gene is knocked out using Cre-loxp gene knock-out technology.
The knockout strategy is to knock out the Gm20541 gene by adopting Cre-loxP knockout technology. However, in other embodiments, there are many technical means for implementing gene knockout, such as CRISPR/Cas9 technology, artificial nuclease-mediated zinc finger nuclease technology (ZFN), transcription activator-like effector nuclease Technology (TALEN), and the like. Therefore, in other embodiments, the Gm20541 gene is knocked out by using CRISPR/Cas9 technology or other technical means, which also belongs to the protection scope of the present invention.
Further, in some embodiments of the invention, the target animal is a mammal.
Further, in some embodiments of the present invention, the mammal is selected from any one of a mouse, a rat, a dog, a pig, a monkey, and a ape.
It should be noted that the target animal of the present invention is not limited to the above-mentioned animals, and other types of mammals are also possible, and any animal may be selected as long as it is an animal having the Gm20541 gene or a homologous gene thereof, and it is also within the scope of the present invention that the Gm20541 gene is knocked out in its precursor cell to express a characteristic of a retinal pigment degeneration disease as a model of the retinal pigment degeneration disease.
In a second aspect, the embodiments of the present invention provide applications of the retinal pigment degeneration disease model obtained by the above method in research of retinal pigment degeneration diseases.
Further, in some embodiments of the invention, the study is directed to treatment of a non-disease.
The animal model obtained by the construction method has the characteristics of typical retinitis pigmentosa diseases, has very wide application prospect, and provides a basis for deeply understanding and researching the retinitis pigmentosa diseases by using the animal model for researching the pathogenesis of the retinitis pigmentosa diseases. Or screening a drug for preventing or treating a retinal pigment degeneration disease, evaluating the efficacy or prognosis of the drug, or the like.
In a third aspect, the embodiments of the present invention provide an application of the retinal pigment degeneration disease model obtained by the above method in screening a drug for preventing or treating retinal pigment degeneration diseases.
Based on the construction method provided by the first aspect of the present invention, those skilled in the art will easily understand that the retinal pigment degeneration disease model obtained by the method can be used for screening drugs for preventing or treating retinal pigment degeneration diseases or other similar fields, which also belongs to the protection scope of the present invention.
Further, in some embodiments of the invention, the use comprises: administering a drug candidate to the retinal pigment degeneration disease model, indicating that the drug candidate may act as a drug for preventing or treating retinal pigment degeneration disease if the retinal pigment degeneration disease model undergoes at least one of the following changes before and after administration of the drug candidate:
(1) after administration of the drug candidate, the retinal pigment degeneration disease model has improved vision compared to before administration of the drug candidate;
(2) (ii) after administration of the drug candidate, the retinal outer nuclear layer of the retinal pigmented degenerative disease model is thickened compared to before administration of the drug candidate;
(3) after administration of the drug candidate, the retinal outer segment of the retinal pigmented degenerative disease model increases compared to before administration of the drug candidate.
In a fourth aspect, an embodiment of the present invention provides a method for breeding a retinal pigment degeneration disease model, which includes: the retinal pigment degeneration disease model obtained by the method described above was selfed.
On the basis of the retinal pigment degeneration disease model obtained by the construction method of the first aspect, in order to obtain more retinal pigment degeneration disease models, the skilled person will easily think that the retinal pigment degeneration disease model obtained by the construction method described above is directly selfed to breed or breed more retinal pigment degeneration disease models, which also belongs to the protection scope of the present invention.
Drawings
In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings needed to be used in the embodiments will be briefly described below, it should be understood that the following drawings only illustrate some embodiments of the present invention and therefore should not be considered as limiting the scope, and for those skilled in the art, other related drawings can be obtained according to the drawings without inventive efforts.
FIG. 1: detecting the expression of the Gm20541 gene in different tissues and organs;
in the figure: a: RT-PCR detection results of expression results of GM20541 gene in different tissues and organs, Brain: brain tissue; liver: a liver; retina: retina, Intestine: a bowel; music: a muscle; heart: a heart; kidney: the kidney; spleen: a spleen; b: statistical results of a in fig. 1; western Blot for detecting the expression of GM20541 protein in different tissues and organs; d, the statistical result of C in figure 1.
FIG. 2: a construction route of a Gm20541 gene knockout mouse;
SixKO or cKO in the figure indicates Gm20541 knock-out homozygous mice; ctr means wild type; het means heterozygote.
FIG. 3: identifying the result of the first-generation mouse by using middle-long distance PCR;
in the figure: a: amplifying a 5 ' end long arm by using a primer pair Gm5 ' LRF and SA3 ' R, wherein the amplification product is 2.3 kb; wherein A2,3,6,9,10, B1 is positive; b: the 3 'long arm was amplified using the primer pair NeoF and Gm 3' LRR, resulting in an amplification product of 2.6 kb. Wherein: a2,3,6,9,10, B6,9, ES1G, ES2G are positive heterozygotes, and +/- + is a wild-type control.
FIG. 4: identifying a Gm20541 gene knockout mouse;
a: the genotype identification result of the Gm20541 gene knockout mouse; b: the gene knockout efficiency of the Gm20541 knockout mouse retina is analyzed through a real-time quantitative PCR experiment, and the Gm20541 is proved to be no longer expressed in the knockout mouse retina; SixKO or cKO represents Gm20541 knockout homozygous mice; ctr means wild type; het means heterozygote.
FIG. 5: dark adaptation Electroretinogram (ERG) test results;
in the figure: A-C: dark adaptation electroretinogram trace graphs of Gm20541 knockout mice under different light intensities; d: dark adaptation electroretinogram a-wave statistics of Gm20541 gene knockout mice under different light intensities; e: dark adaptation electroretinogram b-wave statistics of Gm20541 gene knockout mice under different light intensities; scotopic amplitude: measuring the peak value by dark light; flashlntensity: flash intensity; a-wave: a wave; b-wave: b wave.
FIG. 6: photoadaptive Electroretinogram (ERG) measurements;
in the figure: A-B: a light-adaptive electroretinogram trace map of a Gm20541 knockout mouse under different light intensities; c: 20cd s/m2Light-adapted scintillation (Flicker) electroretinogram trace of Gm20541 knockout mice under light intensity; d: light adaptation electroretinogram a-wave statistics of the Gm20541 gene knockout mouse under different light intensities; e: light adaptation electroretinogram b-wave statistics of the Gm20541 gene knockout mouse under different light intensities; f: 20cd s/m2Light adaptation of Gm20541 knockout mice under light intensityScintigraphic (Flicker) electroretinogram statistics. SixKO or cKO represents Gm20541 knockout homozygous mice; ctr means wild type; het means heterozygote.
FIG. 7: performing immunohistochemical staining on a mouse retina section by specifically knocking out a Gm20541 gene from a retina precursor cell; age of the mice: 4 months; and OS: outer-segment; IS: inner-segment; ONL: outer nuclear layer; INL: inner nuclear layer;
in the figure: a: h & E staining results of mouse retina paraffin sections with Gm20541 genes specifically knocked out by retina precursor cells show that an outer nuclear layer and an inner nuclear layer are thinned; b: and counting the thickness of the outer nuclear layer of the retina of the Gm20541 knockout mouse at different positions.
FIG. 8: the IHC staining result of a mouse with a specific knockout Gm20541 gene of a retinal precursor cell shows that the mouse with the Gm20541 knockout retinal outer segment is shortened and degenerated. SixKO represents Gm20541 knockout homozygous mice; ctr refers to wild-type mouse; DAPI (4', 6-diamidino-2-phenylindole): the nuclear dye 4', 6-diamidino-2-phenylindole; rhodopsin: rhodopsin antibodies; merge: the two colors overlap.
Detailed Description
In order to make the objects, technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below. The examples, in which specific conditions are not specified, were conducted under conventional conditions or conditions recommended by the manufacturer. The reagents or instruments used are not indicated by the manufacturer, and are all conventional products available commercially.
The features and properties of the present invention are described in further detail below with reference to examples.
Example 1
1, detecting the expression condition of the Gm20541 gene in different tissues and organs by adopting an RT-PCR method.
The method comprises the following steps: total RNAs of mouse brain, liver, retina, intestine, muscle, heart, kidney and spleen were extracted, respectively, and then cDNA was synthesized using a cDNA synthesis kit (Invitrogen, Waltham, MA, USA). Primers were designed based on the cDNA sequence of Gm 20541:
Gm20541-cDNA-F:5’-TCGGTCTCATCTTCATTCCC-3';
Gm20541-cDNA-R:5’-GGAAGGCTCTGTTCCGGTAT-3'。
RT-PCR was performed using the extracted cDNA as a template. The results of electrophoresis after amplification are shown in FIG. 1.
The results are shown in A and B in FIG. 1, and it can be seen that the expression of the Gm20541 gene in mouse brain, liver, retina, intestine, muscle, heart, kidney and spleen is detected by RT-PCR method, and as a result, the expression of Gm20541 is found in all the tissues and organs, which indicates that the gene may play an important function in vivo.
2, the expression of the Gm20541 gene in different tissues and organs is detected by adopting an immunoblotting (western blot) method.
The method comprises the following steps:
(1) the mouse brain, liver, retina, heart, kidney and spleen were obtained separately, and 200. mu.l of protein lysate RIPA was added after sufficient grinding.
(2) After cell disruption by sonication, the cells were lysed on ice for 20 min.
(3) Centrifuging at 16000g for 10min at 4 deg.C, transferring the supernatant to another clean centrifuge tube, adding 50 μ l protein sample solution, mixing, and heating at 95 deg.C for 5min.
(4) After the sample was cooled, 20. mu.l of each sample was subjected to polyacrylamide gel electrophoresis (SDS-PAGE) at 160V to separate proteins.
(5) After SDS-PAGE is finished, cutting a nitrocellulose membrane with a proper size according to needs, sequentially laying filter paper, glue, the nitrocellulose membrane and the filter paper, removing bubbles, putting a membrane transferring groove into an ice water bath, and transferring the membrane for 2 hours by adopting a constant current of 0.28A.
(6) After the film transfer is finished, the nitrocellulose film is washed once by pure water, dried and marked. Then blocked with 8% skimmed milk for 2 h.
(7) After blocking was complete, a defined amount of primary antibody diluted in blocking solution in a defined ratio (according to the instructions for antibody use) was added and incubated overnight at 4 ℃.
(8) The primary antibody was recovered and the membrane was washed 4 times with 1 × TBST buffer for 10min each time, and depending on the source of the primary antibody, the appropriate secondary antibody was selected, and horseradish catalase (HRP) -labeled secondary antibody was diluted with 1 × TBST and incubated for 2h on a shaker at room temperature.
(9) After the secondary antibody incubation was completed, the membrane was washed 3 times with 1 XTSST for 10min each time, and the protein was detected using Thermo's ELC luminescence kit using Bio-Rad's chemiluminescence gel imaging system.
The results are shown in fig. 1C and D, and it can be seen that the Gm20541 protein was demonstrated to be expressed in mouse brain, liver, retina, heart, kidney and spleen by the method of immunoblotting (western blot).
Example 2
In this embodiment, a mouse is used as a target animal to explain the method for constructing a retinal pigment degeneration disease model provided by the present invention, and the Gm20541 gene knockout route is shown in fig. 2, and the specific operations are as follows:
obtaining a knockout mouse:
1 cloning 5 'arm homologous with mouse Gm20541 gene, an expression frame containing reporter gene GFP, an expression frame with NEO resistance gene, 3 rd exon with loxP sites arranged in the same direction at two ends and 3' end arm into BAC vector (figure 2) to replace 3 rd exon of Gm20541 gene to be knocked out;
2, replacing the 3 rd exon in the Gm20541 gene by using a DNA homologous recombination technology to obtain a mouse embryonic stem cell conditionally knocked out by the Gm20541 gene;
3, preparing a chimeric mouse containing a Gm20541 gene knockout cell by using the embryonic stem cell obtained in the step 2 (figure 2);
4, the chimera mouse obtained in the step 3 and a wild mouse are bred by mating, and a heterozygous mouse with a Gm20541 gene knockout is selected in the offspring (FIG. 2).
And (3) identification:
in the experiment for identifying the positive first-generation mice by long-distance PCR in example 2, the amplification 5 ' end long arm uses a primer pair Gm5 ' LRF and SA3 ' R, and the amplification product is 2.3 Kb.
Gm 5’LRF:5’-GGCAGGATCTTCACCTGTTGACCAACATGCCT-3’;
SA3’R:5’-CCAACCCCTTCCTCCTACATAGTTGGCAGT-3’。
The result is shown in FIG. 3, panel A, and the amplification product was 2.3 kb. Wherein A2,3,6,9,10, B1 are positive.
Primers were used to amplify the 3' long arm:
NeoF:5’-CGCCTT CTTGACGAG TTCTTCTGA-3’;
Gm 3’LRR:5’-GGTGCTTGAGTAGTGTTGAATCTCAGTGGACCA-3’
the result is shown in FIG. 3B, and the amplification product was 2.6 kb. Wherein: a2,3,6,9,10, B6,9, ES1G, ES2G are positive heterozygotes, and +/- + is a wild-type control.
5, mating and breeding the heterozygote mouse animal obtained in the step 4 with a transgenic mouse FLPer mouse to obtain a Gm20541 gene conditional knockout heterozygote mouse;
6, mutually mating and breeding the Gm20541 gene conditional knockout heterozygous mice obtained in the step 5 to obtain Gm20541 gene conditional knockout homozygous mice;
7, mating the Gm20541 gene conditional knockout homozygote animal obtained in the step 6 with a Six3-Cre gene transfer animal to obtain a retina precursor cell Gm20541 gene knockout mouse.
Transgenic mice FLPer mice were purchased from the U.S. Czewson laboratory (strain name: B6.129S4-Gt (ROSA)26Sortm1(FLP1) Dym/RainJ). Six3-Cre transgenic mice (MGI: 3574771) were donated by the Anderson cancer center, university of Texas, USA. Six3 is a marker transcription factor of forebrain ventral and retinal precursor cells, the specificity of the transcription factor drives Cre gene to express in the retinal precursor cells, Cre protein can enter cell nucleus to recognize LoxP sites on genome, and gene knockout is realized.
Identifying a knockout mouse:
the genotype identification of the mouse with the retinal precursor cell knockout of the Gm20541 gene is carried out as follows:
(1) cutting a little tissue sample from the tail tip of the mouse, and placing the cut tissue sample in a clean 1.5ml centrifuge tube;
(2) add 100. mu.l lysis buffer (40mM NaOH, 0.2mM EDTA solution) to the centrifuge tube and heat for 1h at 100 ℃ in a metal bath; (3) the centrifuge tube was removed, cooled to room temperature, 100. mu.l of a neutralizing solution (40mM Tris-HCl, pH5.5) was added thereto, and after centrifugation at 10000g for 2min, the supernatant was used for mouse genotyping.
(3) And (3) PCR amplification: the PCR reaction system was configured as follows
2×Taq Mix: 10μL
Tail tissue lysate: 2 μ L
Primer 1(Gm20541-loxP-Forward or Six 3-Cre-Forward): 1 μ L (concentration: 10mM)
Primer 2(Gm20541-loxP-Reverse or Six 3-Cre-Reverse): 1 μ L (concentration: 10mM)
ddH2O: 6μL。
The primer sequences are as follows:
gm20541-loxP-Forward sequence: 5'-ATTCCCCTTCAAGATAGCTAC-3', respectively;
gm20541-loxP-Reverse sequence: 5'-AATGATCAACTGTAATTCCCC-3', respectively;
six3-Cre-Forward sequence: 5'-GCCGCCGGGATCACTCTCG-3', respectively;
six3-Cre-Reverse sequence: 5'-CCAGCCGCCGTCGCAACTC-3' are provided.
And (3) amplification procedure: after the PCR reaction system was prepared, the template DNA was fully denatured by preheating at 95 ℃ for 5 minutes in a PCR instrument, and then subjected to an amplification cycle. In each cycle, the template is denatured by keeping the temperature at 95 ℃ for 30 seconds, then the temperature is reduced to the renaturation temperature of 58 ℃ and kept for 30 seconds, so that the primer and the template are fully annealed; the reaction mixture was held at 72 ℃ for 30 seconds, and the primers were extended on the template to synthesize DNA, thereby completing one cycle. This cycle was repeated 25 times to allow the amplified DNA fragments to accumulate in large amounts. Finally, the product was left intact for 5 minutes at 72 ℃ and stored at 4 ℃.
(4) Gel electrophoresis
1g of agarose was weighed and placed in 100ml of TAE buffer, and melted in a microwave oven to prepare 1% agarose gel. 10 μ l of PCR product was placed in a well and subjected to 120V constant pressure agarose electrophoresis for 15min.
In FIG. 4, the upper part of A is the result of conditional knockout identification of Gm20541, WT represents the wild-type control, and the size of the band is 223 bp; het represents heterozygote, and two bands are 223bp and 358 bp; SixKO represents homozygote, and the band size is 358 bp. In FIG. 4, the result of Six3-Cre identification is shown below A. The size of Six3-cre is 200 bp. From the results of A in FIG. 4, it is shown that the employed identification method can effectively identify the genotype of the newborn mouse. The Gm20541 gene knockout homozygote mouse can be used as a retinal pigment degeneration disease model (SixKO or cKO is used for representing the Gm20541 gene knockout homozygote mouse; Ctr is a wild type; Het is a heterozygote) and relevant phenotype verification is carried out.
(5) The RT-PCR experiment analyzes the gene knockout efficiency verification in the retina of the Six3-cre knockout mouse, and the method comprises the following steps:
(a) separating the wild type mouse retina tissue and the mutant mouse retina tissue respectively, placing the tissues in a 1.5ml centrifuge tube, adding 1ml of Trizol extracting solution, and keeping the temperature at room temperature for 20 minutes;
(b) adding 200 mul chloroform, fully and uniformly mixing, and standing for 10 minutes at room temperature;
(c) placing the sample in a 4-degree centrifuge, centrifuging for 15 minutes at 10000 revolutions;
(d) carefully sucking the supernatant, adding isopropanol with the same volume, fully and uniformly mixing, centrifuging at 10000 rpm to precipitate RNA;
(e) washing the total RNA separated out by 75% ethanol, centrifuging, precipitating again, then airing and adding DEPC water for dissolving;
(f) the extracted total RNA was used to synthesize cDNA using a cDNA synthesis kit (Invitrogen, Waltham, MA, USA). Primers were designed based on the cDNA sequence of Gm 20541:
Gm20541-cDNA-F:5’-TCGGTCTCATCTTCATTCCC-3';
Gm20541-cDNA-R:5’-GGAAGGCTCTGTTCCGGTAT-3';
(g) RT-PCR was performed using the extracted cDNA as a template. After amplification, electrophoresis was performed.
The results are shown in B in FIG. 4, and it can be seen that the expression level of Gm20541 in the retina of a Gm20541 gene knockout homozygous mouse is significantly reduced by RT-PCR detection. Ctrl in B of FIG. 4 refers to wild-type control, SixKO refers to Gm20541 knock-out homozygote mouse; gm20541 RNA level means that the RNA expression level is relatively changed, and the wild type expression level is 1.
Example 3
ERG visual acuity test was performed on 4-month-old Gm20541 knockout homozygous mice:
1 dark adaptation animals should adapt dark overnight, and the environment should be absolutely free of light;
anesthesia is performed for 2 days: weighing, and injecting in an abdominal cavity; deep anesthesia is suitable;
animal fixation and mydriasis: after completion of anesthesia, mice were taped in front of the animal test platform under dark red light illumination: the mouse needs to be ensured to lie prone, namely, the height of two eyes is consistent relative to the stimulating port of the flash stimulator, the eyes are fully exposed, and the mydriatic agent is dripped.
4, electrode installation: preheating an electroretinograph (Espion Visual Electrophysiology System, diagnosllc, Littleton, MA, USA), coating conductive paste on the ear clip electrode, clipping the tail, and inserting the amplifier "ground" interface; the double-ended needle electrode is inserted into the nape skin (approximately in the middle of the ears) and simultaneously connected with the negative interfaces of the two channels; the gold ring electrode was clamped to the electrode holder of the animal experiment platform and carefully angled to slightly contact the central apex of the cornea. One channel anode is connected with the right eye, and the two channel anode is connected with the left eye. The needle tube is used for dripping physiological saline on the eyes, so that the contact effect of the gold ring electrode and the cornea is improved. The two gold ring electrodes are ensured to contact the same position of the central positive end of the cornea of two eyes in the same angle and mode.
And 5, after the oscillography signal is recorded to confirm that the oscillography signal is correct, the dark red light is turned off. The dark adaptive light intensity of 0.003 cd.s/m can be recorded by first trying2The ERG detection of (a), confirms the quality of the signal: if a large difference from the expected amplitude occurs in the amplitudes of both eyes, it is recommended to check the mounting position of the gold ring electrode again. Then the dark adaptive light intensity is recorded as 0.3/3.0/20.0 cd.s/m2Of the signal of (1). It should be noted that dark adaptation is performed at 20.0cd s/m2After the light intensity is detected, the system will automatically turn on the backlight. Similarly, a timer is started, and the light is adapted for 10-15 minutes and recorded again.
6 after the optical adaptation, the optical adaptation of 3.0 cd.s/m is recorded in sequence2And 20.0cd · s/m2The waveform under the light intensity is finally recorded as 20.0cd s/m2The retina evoked potential flickers under light intensity.
Results it was found that at 4 months, compared to Ctrl (control) mice, cKO (Gm20541 knockout homozygous mice) mice had a and b waves significantly reduced under both dark and light acclimation conditions, indicating impaired vision following Gm20541 knockout (see fig. 5 and 6).
Example 4
Retinal paraffin sections H & E staining:
the retinas of 4-month-old mice were subjected to paraffin sectioning and staining by hematoxylin-eosin staining (H & E staining method) as follows:
1) quickly taking eyeball tissues of the mouse, and placing the eyeball tissues in a stationary liquid for fixation for 24 hours;
2) embedding in paraffin, and slicing to obtain slices with a thickness of 4 μm;
3) the slices were dewaxed conventionally with xylene, washed with multi-stage ethanol to water: xylene (I)5min → xylene (II) 5min → 100% ethanol 2min → 95% ethanol 1min → 80% ethanol 1min → 75% ethanol 1min → distilled water washing 2 min;
4) hematoxylin staining for 5 minutes and washing with tap water;
5) ethanol hydrochloride is differentiated for 30 seconds;
6) soaking in tap water for 15 minutes;
7) placing in eosin solution for 2 minutes.
8) Conventional dehydration, transparency, mounting: 95% ethanol (I)1min → 95% ethanol (II) 1min → 100% ethanol (I)1min → 100% ethanol (II) 1min → xylenecarbonate (3: 1) 1min → xylene (I)1min → xylene (II) 1min → neutral resin sealing.
9) Take pictures under microscope.
The results found that at 4 months, the outer nuclear layer of the retina of SixKO mice had begun to thin, indicating photoreceptor cell death, compared to Ctrl (control) mice (fig. 7).
Example 5
Immunostaining of frozen retinal sections: after 4-month-old mice with the Gm20541 gene knockout homozygote obtained in example 2 were sacrificed at the neck, the eyeballs were quickly removed and placed in 4% PFA, fixed on ice for 15min, and then the cornea was cut and fixed on ice. After 2h, washing with PBS buffer solution for 3 times, then placing the eyeball in 30% sucrose solution for dehydration for 2h, then cutting off cornea and crystal under a dissecting mirror, embedding with OCT, and rapidly placing in a refrigerator at-80 ℃ for freezing. After about 10min, the OCT embedded eyeball is taken out and placed in a freezing microtome to be balanced at-25 ℃ for about 30min, and then the section can be obtained. The slice thickness was 12 μm.
After the slicing was completed, the higher quality slices were selected and placed in an oven at 37 ℃ for 30min, then an immunohistochemical pen was circled in the area with retinal tissue, washed three times with PBS to remove OCT, then blocked with 5% NDS (containing 0.25% Triton) for permeation for 2h, incubated primary antibody at 4 ℃ overnight. On the following day, after three washes with PBS, the corresponding fluorescent secondary antibody was incubated, then washed three more times with PBS, mounted, and observed.
The results are shown in fig. 8, and at the age of 4 months, after the mice are stained by retina frozen tissue sections with outer segment antibody Rhodopsin and inner segment antibody NaK-Atpase, the Gm20541 knockout homozygote mice (SixKO in the figure) have obviously shortened retina outer segments compared with wild-type mice, and show obvious degeneration characterization.
In conclusion, in the embodiment of the invention, a mouse is taken as an example, the Gm20541 gene is specifically knocked out in a mouse retina precursor cell by a Cre-loxP gene knocking-out technology, and the mouse shows typical characteristics of retinal pigment degeneration diseases such as impaired vision, short and degenerated outer segment of an optic cell, lost optic cell and the like. It is fully demonstrated that the target animal can express a retinal pigment degeneration disease by knocking out the Gm20541 gene in retinal precursor cells. The retina precursor cell knockout Gm20541 gene animal can be used as a retinal pigment degeneration disease model. The disease model can be used in the fields of research on retinal pigment degeneration diseases and the like, and provides a new model for the research on the diseases, such as the pathogenesis process, mechanism and screening of related medicines.
Although the examples of the present invention only show the phenotype of the mouse with the knockout of the Gm20541 gene in the retinal precursor cells, it is easily understood by those skilled in the art that the mouse as a representative of mammals should have a similar phenotype with the knockout of the Gm20541 gene or its homologous gene in other mammals, which can also be used as a model of retinal pigment degeneration disease.
The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention, and various modifications and changes may be made by those skilled in the art. Any modification, equivalent replacement, or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
SEQUENCE LISTING
<110> Hospital for people in Sichuan province
<120> method for constructing retinal pigment degeneration disease model by using Gm20541 gene and application
<160>1
<170>PatentIn version 3.5
<210>1
<211>1406
<212>DNA
<213> Artificial sequence
<400>1
gaatgcagtg acctatgatg atgtgtgtgt gaacttcact ctggaagaat ggactttact 60
ggatccttca cagaagagtc tctacagaga tgtgatgcag gaaacctaca ggaatctcac 120
tgctataggc tacaattggg aagatgacaa tattgaagac tattttcaaa gttctagaag 180
acatggaagg catgaaagaa atcatagtgg agagaaacct tatgcttgta accaatgtga 240
taaagccttt tcatgtcatc atagtctcca aatacataaa agaagacata ctggagagaa 300
actctatgaa tgtaaccgtt gtaataaagg ctttccatat cccagtgctc tacaaataca 360
taaaaggata cacagtggag agaaacccta tgaatgtaaa caatgtggta aagcctttgc 420
atgtcacagt tctcttcaaa ggcatgaaag aatacatact ggtgagaaac cttatgaatg 480
tagccaatgt ggtaaagcct ttacacatca aaagagtctc caaatacata aaagaactca 540
cagtggagaa aaaccatatg ggtgtagtca gtgtggaaaa gactttgtaa gtcagagtcg 600
tcttctagaa cataaaagga cacatactgg agagaaaccc tatgaatgta accaatgtgg 660
taaagccttt gcatattcca acagtctcca aatacatcaa agaacacaca ctggagagaa 720
accctatgaa tgtaaccagt gtggtaaagc ctttgcatat cacaatagtc tccaaataca 780
taaaagtaca cacactggag agaaacccta taaatgtaac cagtgtggta aagcctttgc 840
atatcacatt actctccgaa cacataaagg aacacacact gaagagaaac cctatgaatg 900
taaccaatgt ggtaaagcct ttgcatattc caacagtctc caaatacatc aaagaacaca 960
cactggagag aaaccctatg aatgtaacca gtgtggtaaa gcctttgcat atcacaatag 1020
tctccaaata cataaaagta cacacactgg agagaaaccc tatgaatgta accagtgtgg 1080
taaagccttt gtatgtagca gtcattttca aaggcataaa aaaattcata ctggagagaa 1140
accctatgat tgtaaccagt gtggtaaagc ctttgcatat aaaagtaatc tccaaattca 1200
tgaaagaaaa cacactggagggaaaccctc tgaatgtaat taatgtagta aagcttttgc 1260
atttcataat agtttccaaa tacataaaag aacacatagt gagagaaacc ctatgaatat 1320
aaccaatgtg gtaaaacatt tccatatctc agtggtctcc gcatttataa cagaacacat 1380
agtggagaga aaccctatgg atgtaa 1406
Claims (10)
1. A method for constructing a retinal pigment degeneration disease model by using a Gm20541 gene is characterized by comprising the following steps: knocking out the Gm20541 gene in the target animal retina precursor cell genome.
2. The method of claim 1, wherein the Gm20541 gene knockout refers to the knockout of an exon sequence of the Gm20541 gene.
3. The method of claim 2, wherein the exon sequences are selected from any one or more of exon 1, exon 2 and exon 3 sequences.
4. The method of claim 3, wherein the exon sequences are exon 3 sequences.
5. The method of claim 4, wherein the method comprises: knocking out the 3 rd exon sequence on the Gm20541 gene by using a Cre-loxp gene knockout technology.
6. The method of any one of claims 1-5, wherein the target animal is a mammal;
preferably, the mammal is selected from any one of mice, rats, dogs, pigs, rabbits, cows, horses, sheep, monkeys, and apes.
7. Use of the retinal pigment degeneration disease model obtained by the method of any one of claims 1 to 6 in the study of retinal pigment degeneration diseases.
8. Use of the retinal pigment degeneration disease model obtained by the method according to any one of claims 1 to 6 for screening a medicament for preventing or treating retinal pigment degeneration disease.
9. The application according to claim 8, wherein the application comprises: administering a drug candidate to the retinal pigment degeneration disease model, indicating that the drug candidate may act as a drug for preventing or treating retinal pigment degeneration disease if the retinal pigment degeneration disease model undergoes at least one of the following changes before and after administration of the drug candidate:
(1) after administration of the drug candidate, the retinal pigment degeneration disease model has improved vision compared to before administration of the drug candidate;
(2) (ii) after administration of the drug candidate, the retinal outer nuclear layer of the retinal pigmented degenerative disease model is thickened compared to before administration of the drug candidate;
(3) after administration of the drug candidate, the retinal outer segment of the retinal pigmented degenerative disease model increases compared to before administration of the drug candidate.
10. A method for breeding a retinitis pigmentosa disease model is characterized by comprising the following steps: selfing a retinal pigment degeneration disease model obtained by the method of any one of claims 1-6.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010114903.8A CN111269945B (en) | 2020-02-25 | 2020-02-25 | Method for constructing retinal pigment degeneration disease model by using Gm20541 gene and application |
US17/416,869 US20220049310A1 (en) | 2020-02-25 | 2020-10-20 | Use of ZNF124 Gene in Early Screening or Auxiliary Diagnosis of Retinitis Pigmentosa Disease |
PCT/CN2020/122230 WO2021169333A1 (en) | 2020-02-25 | 2020-10-20 | Use of znf124 gene in early screening or auxiliary diagnosis of retinitis pigmentosa diseases |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010114903.8A CN111269945B (en) | 2020-02-25 | 2020-02-25 | Method for constructing retinal pigment degeneration disease model by using Gm20541 gene and application |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111269945A true CN111269945A (en) | 2020-06-12 |
CN111269945B CN111269945B (en) | 2021-04-02 |
Family
ID=70995255
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010114903.8A Active CN111269945B (en) | 2020-02-25 | 2020-02-25 | Method for constructing retinal pigment degeneration disease model by using Gm20541 gene and application |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111269945B (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111484981A (en) * | 2020-04-26 | 2020-08-04 | 四川省人民医院 | Method for constructing retinal neovascular disease model and application |
CN111785370A (en) * | 2020-07-01 | 2020-10-16 | 医渡云(北京)技术有限公司 | Medical record data processing method and device, computer storage medium and electronic equipment |
CN111778281A (en) * | 2020-07-17 | 2020-10-16 | 四川省人民医院 | Construction method and application of retina bipolar cytopathy model |
CN112715484A (en) * | 2020-12-29 | 2021-04-30 | 四川省人民医院 | Method for constructing retinal pigment degeneration disease model, application and breeding method |
WO2021169333A1 (en) * | 2020-02-25 | 2021-09-02 | 四川省人民医院 | Use of znf124 gene in early screening or auxiliary diagnosis of retinitis pigmentosa diseases |
CN113621649A (en) * | 2021-09-14 | 2021-11-09 | 商丘市第一人民医院 | Construction method and application of retinal pigment degeneration disease model |
CN114916502A (en) * | 2022-07-07 | 2022-08-19 | 电子科技大学 | Construction method and application of retinal pigment degeneration disease model |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108029638A (en) * | 2017-12-04 | 2018-05-15 | 四川省人民医院 | A kind of construction method of retina pigment denaturation animal model and application |
CN109182355A (en) * | 2018-09-17 | 2019-01-11 | 四川省人民医院 | The construction method of retinal neovascularization disease model and application |
-
2020
- 2020-02-25 CN CN202010114903.8A patent/CN111269945B/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108029638A (en) * | 2017-12-04 | 2018-05-15 | 四川省人民医院 | A kind of construction method of retina pigment denaturation animal model and application |
CN109182355A (en) * | 2018-09-17 | 2019-01-11 | 四川省人民医院 | The construction method of retinal neovascularization disease model and application |
Non-Patent Citations (1)
Title |
---|
CLAUDIO MUSSOLINO ET AL.: "Zinc-finger-based transcriptional repression of rhodopsin in a model of dominant retinitis pigmentosa", 《EMBO MOL MED》 * |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021169333A1 (en) * | 2020-02-25 | 2021-09-02 | 四川省人民医院 | Use of znf124 gene in early screening or auxiliary diagnosis of retinitis pigmentosa diseases |
CN111484981A (en) * | 2020-04-26 | 2020-08-04 | 四川省人民医院 | Method for constructing retinal neovascular disease model and application |
CN111484981B (en) * | 2020-04-26 | 2021-02-02 | 四川省人民医院 | Method for constructing retinal neovascular disease model and application |
CN111785370A (en) * | 2020-07-01 | 2020-10-16 | 医渡云(北京)技术有限公司 | Medical record data processing method and device, computer storage medium and electronic equipment |
CN111785370B (en) * | 2020-07-01 | 2024-05-17 | 医渡云(北京)技术有限公司 | Medical record data processing method and device, computer storage medium and electronic equipment |
CN111778281A (en) * | 2020-07-17 | 2020-10-16 | 四川省人民医院 | Construction method and application of retina bipolar cytopathy model |
CN112715484A (en) * | 2020-12-29 | 2021-04-30 | 四川省人民医院 | Method for constructing retinal pigment degeneration disease model, application and breeding method |
CN112715484B (en) * | 2020-12-29 | 2022-04-22 | 四川省人民医院 | Method for constructing retinal pigment degeneration disease model, application and breeding method |
CN113621649A (en) * | 2021-09-14 | 2021-11-09 | 商丘市第一人民医院 | Construction method and application of retinal pigment degeneration disease model |
CN113621649B (en) * | 2021-09-14 | 2023-05-26 | 商丘市第一人民医院 | Construction method and application of retinal pigment degeneration disease model |
CN114916502A (en) * | 2022-07-07 | 2022-08-19 | 电子科技大学 | Construction method and application of retinal pigment degeneration disease model |
Also Published As
Publication number | Publication date |
---|---|
CN111269945B (en) | 2021-04-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111269945B (en) | Method for constructing retinal pigment degeneration disease model by using Gm20541 gene and application | |
CN112715484B (en) | Method for constructing retinal pigment degeneration disease model, application and breeding method | |
CN113621649B (en) | Construction method and application of retinal pigment degeneration disease model | |
CN108029638B (en) | Construction method and application of animal model of retinitis pigmentosa disease | |
Kaiser et al. | Transgenic labeling of parvalbumin-expressing neurons with tdTomato | |
CN114561408B (en) | Construction method and application of retinal pigment degeneration disease model | |
CN111500640B (en) | Construction method and cultivation method of RP disease model | |
CN114916502B (en) | Construction method and application of retinal pigment degeneration disease model | |
CN115176760B (en) | Method for constructing retinal pigment degeneration disease model, application and breeding method | |
Narfström et al. | The domestic cat as a large animal model for characterization of disease and therapeutic intervention in hereditary retinal blindness | |
WO2019080667A1 (en) | Method for constructing ataxia animal model and application thereof | |
Greenwald et al. | S-opsin knockout mice with the endogenous M-opsin gene replaced by an L-opsin variant | |
Domènech et al. | A new Cerkl mouse model generated by CRISPR-Cas9 shows progressive retinal degeneration and altered morphological and electrophysiological phenotype | |
Nguyen et al. | USH2A gene mutations in rabbits lead to progressive retinal degeneration and hearing loss | |
Raymond et al. | A Thy1-CFP DBA/2J mouse line with cyan fluorescent protein expression in retinal ganglion cells | |
CN111778281B (en) | Construction method and application of retina bipolar cytopathy model | |
US11653636B2 (en) | Method of making a rat model of retinal degeneration and rat model made thereby | |
Sechrest et al. | Structural and functional rescue of cones carrying the most common cone opsin C203R missense mutation | |
CN117296799B (en) | Construction method and application of retinal pigment degeneration disease model | |
WO2021169333A1 (en) | Use of znf124 gene in early screening or auxiliary diagnosis of retinitis pigmentosa diseases | |
CN117230077B (en) | Application of Hakai gene in RP disease model construction and construction method | |
Bao et al. | Human RGR gene and associated features of age-related macular degeneration in models of retina-choriocapillaris atrophy | |
CA2522597C (en) | Mouse deficient in glutamate transporter glast function | |
KR102612878B1 (en) | eif2b3 knock-out animal model and using thereof | |
CN117305364A (en) | Method for constructing retina degeneration disease model by using gene manipulation technology and application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |